## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `retatrutide-post-surgery`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/retatrutide-post-surgery/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/retatrutide-post-surgery/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/retatrutide-post-surgery/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/retatrutide-post-surgery/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/retatrutide-post-surgery/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/retatrutide-post-surgery/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `retatrutide-post-surgery` v2 · content_hash `1f914ba63fe78c48…` · thread_head genesis · 23 DIVs
- **thesis (c1):** Phase 2 trial showed 24.2% mean weight loss at 12 mg retatrutide vs 2.1% placebo at 48 weeks in adults with obesity.
  - c2 [human/active] Phase 3 TRIUMPH-1 reported up to 28.3% average weight loss at 12 mg over 80 weeks.
  - c3 [mechanistic/active] No published human trials examine retatrutide for post-surgical healing or recovery outcomes.
  - c4 [mechanistic/active] GLP-1 class drugs carry perioperative considerations around gastric emptying and anesthesia risk.
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/retatrutide-post-surgery/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/retatrutide-post-surgery/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `retatrutide-post-surgery`
- **title:** Retatrutide for Post-Surgery Recovery: Weight Loss, Mechanical Load, and Evidence Layers
- **url:** https://miscsubjects.com/a/retatrutide-post-surgery
- **register:** source_ledger
- **updated:** 2026-07-17T02:41:19.857Z
- **tags:** peptide, matrix

## Body

## What's breaking down
Post-surgery recovery involves multiple layers. Surgical sites heal through inflammation, tissue remodeling, and load management. Excess body weight adds compressive force across the body. Every extra pound multiplies stress on healing joints, incisions, and supporting structures. If body weight stays high, mechanical stress can slow tissue repair and raise complication risk.

Metabolic factors also matter. Obesity links to higher inflammation markers and slower wound healing in observational data. Retatrutide targets weight reduction through GLP-1, GIP, and glucagon receptor pathways. This addresses one clear layer: mechanical load from excess mass. It does not act directly on surgical wound repair pathways.

## Why Retatrutide might help you
1. What keeps failing: Excess body weight multiplies compressive load on spine, hips, knees, and surgical sites. Studies estimate roughly four pounds of lumbar force per extra pound of body weight.
2. What Retatrutide is studied to do: Human trials show it drives substantial weight loss via triple-hormone agonism, lowering overall mass without direct tissue regeneration at the surgical site.
3. Therefore for you: If mechanical overload from body weight forms part of your post-surgery challenge, Retatrutide is discussed because it targets that load-reduction layer. It supports repair by decreasing stress rather than suppressing symptoms.

## How these fit together
This is a single-compound focus. Retatrutide maps to the metabolic load and body weight layer. If your profile includes other degeneration factors such as inflammation or sleep disruption, separate tools would address those. Weight loss from Retatrutide can indirectly ease demands on healing tissues by reducing force across the body.

## What the evidence actually shows
Human phase 2 trial data (NEJM 2023) enrolled 338 adults with obesity. Participants received retatrutide or placebo once weekly. At 48 weeks the 12 mg group showed mean weight loss of 24.2 percent versus 2.1 percent on placebo (human tier). Over 80 percent lost at least 15 percent body weight at the highest dose (human tier).

Phase 3 TRIUMPH-1 topline results (2026) reported average losses of 25.9 percent at 9 mg and 28.3 percent at 12 mg over 80 weeks, with some participants reaching 30 percent or more (human tier). These reductions exceed typical lifestyle interventions and approach levels seen after bariatric procedures.

No human trials test retatrutide specifically for post-surgical healing or recovery timelines. Perioperative guidance for GLP-1 class drugs focuses on anesthesia risks such as delayed gastric emptying rather than repair benefits (mechanistic tier).

Animal or preclinical data on retatrutide itself remain limited in public literature and do not address surgical models directly (preclinical tier).

## What scientists say
Researchers describe retatrutide as producing dose-dependent weight reduction with gastrointestinal side effects that are mostly mild to moderate (human tier from phase 2). Heart rate increases occur early and tend to decline later. Cardiovascular risk markers including hsCRP improved alongside weight loss in phase 3 data (human tier). Scientists note the absence of dedicated surgical outcome studies and emphasize individualized perioperative planning for the broader GLP-1 class.

## What people say on Reddit
Anecdotal reports on r/Retatrutide mention resuming the compound after surgery with variable timing. Some users describe temporary pauses around procedures and note weight regain when stopping. Others report continuing through minor procedures without stated issues. These accounts remain individual experiences and carry no controlled comparison (anecdotal tier).

## What people say on X
Posts on X echo similar themes: discussions of holding retatrutide pre- or post-procedure due to general GLP-1 anesthesia considerations. Users share personal weight trajectories but provide no structured outcome data (anecdotal tier).

## What we do not know
Direct evidence linking retatrutide to faster surgical wound closure, reduced scar tissue, or lower post-operative complication rates does not exist in published trials. Optimal timing around surgery, effects on specific procedures such as orthopedic or abdominal cases, and long-term healing metrics remain unstudied in humans. Weight loss benefits are clear from obesity trials, yet translation to post-surgical mechanical relief rests on inference from body-mass changes.

## Safety and limits
Common effects in trials include nausea, vomiting, and diarrhea that increase with dose (human tier). Heart rate elevation appears dose-related. No dedicated safety database covers post-surgical populations. Regulatory status remains investigational; retatrutide is not approved for any use. All considerations stay at the level of published trial observations and class-level perioperative discussions.

Evidence inventory: 2+ large human randomized trials (phase 2 and phase 3 topline), multiple secondary analyses of metabolic markers, zero dedicated surgical-recovery trials, scattered patient anecdotes on forums, no verified X posts with outcome metrics.

## Claims (4)

- **c4** [mechanistic w=0.3] GLP-1 class drugs carry perioperative considerations around gastric emptying and anesthesia risk.
  - who_claims: grok/grok-4.3
  - slot: limitations
  - sources: s3
- **c2** [human w=0.8] Phase 3 TRIUMPH-1 reported up to 28.3% average weight loss at 12 mg over 80 weeks.
  - who_claims: grok/grok-4.3
  - sources: s2
- **c3** [mechanistic w=0.3] No published human trials examine retatrutide for post-surgical healing or recovery outcomes.
  - who_claims: grok/grok-4.3
- **c1** [human w=0.8] Phase 2 trial showed 24.2% mean weight loss at 12 mg retatrutide vs 2.1% placebo at 48 weeks in adults with obesity.
  - who_claims: grok/grok-4.3
  - sources: s1

## Voxel graph (4 atoms · 7 edges)
- full graph: https://miscsubjects.com/api/articles/retatrutide-post-surgery/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (3)
- chain valid: yes · head: `62966681c4ee72c2`

### s1 · pubmed · http_403
- title: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
- url: https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
- summary: Phase 2 randomized trial results showing dose-dependent weight loss.
- quote: At 48 weeks, the least-squares mean percentage change in the retatrutide groups was −24.2% in the 12-mg group, as compared with −2.1% in the placebo group.
- claim_ids: c1
- hash: `7eba59446873d88f`

### s2 · news · ok
- title: Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
- url: https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss
- summary: Topline phase 3 weight loss data.
- quote: In TRIUMPH-1, participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks
- claim_ids: c2
- hash: `c77944927c2def8b`

### s3 · medical · ok
- title: Drugs for Diabetes or Weight Loss: What To Know Before Surgery
- url: https://madeforthismoment.asahq.org/preparing-for-surgery/risks/drugs-diabetes-weight-loss/
- summary: Class-level perioperative guidance for GLP-1 agonists.
- quote: Certain types of medications taken for weight loss or diabetes management can affect the safety of patients when they undergo general anesthesia or deep sedation.
- claim_ids: c4
- hash: `62966681c4ee72c2`

## Provenance (2 model passes)
- chain valid: yes · head: `8ead4fdb3badb6dc`

- write · grok/grok-4.3 · 2026-06-30T00:54 · hash `2c5e5863f664`
- voxel_divide · owner · 2026-07-17T02:41 · hash `8ead4fdb3bad`

## Question graph
- questions: 0 · evidence ingests: 0

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/retatrutide-post-surgery/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/retatrutide-post-surgery/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"retatrutide-post-surgery","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest retatrutide-post-surgery|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim retatrutide-post-surgery|tier|assertion`
- **iMessage ask:** `retatrutide-post-surgery|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `retatrutide-post-surgery`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/retatrutide-post-surgery/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/retatrutide-post-surgery/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*